



2017 CABA
INVESTMENT & ENTREPRENEURSHIP
SYMPOSIUM



CHAIR

BEN YIBIN WEI

CO-CHAIRS


ELLEN FAN

JIAN SHAO

BO YING

PRESIDENT

KEVIN FANG



COMMITTEES

HAO CAI

LAN CAO

QINGQING CAO

QINGLIN CHE

YIN CHEN

ZHIHONG CHEN

CHAOYANG DAI

SHUJIA DAI

RUIYI DONG

JUN HAN

LIUFANG HU

JING HUANG

PENGYU HUANG

JING JIN

JO LEE

SHIWEN LIN

DANDAN LING

CARRIE LIU

WENDY LIU

SUSAN QU

HUILAN REN

JIANYU SHANG

ERIC SHI

XUE SHUI

WINNY WANG

YIHAN WANG

YONGHENG WANG

SHERRY XIAO

CINDY YANG

WENDY YANG

ZHIYONG YANG

CHUNXIAO YU

INGA YU

XIANGYANG YU

PHIL ZHANG

YOUXIN ZHANG

LIPING ZHOU

ZHENDONG ZHU

PROGRAM BROCHURE

JO LEE

LAN CAO

DANDAN LING

SHERRY XIAO

XUE SHUI

Presented by



Co-organizers





2017 CABA INVESTMENT & ENTREPRENEURSHIP SYMPOSIUM

Agenda

08:30 Registration / Continental Breakfast (Foyer)

09:00 Opening Remarks from the Chair (Auditorium)

Ben Yibin Wei, Ph.D., MBA, Director, BD APAC, PerkinElmer
Executive Member, Chinese-American BioMedical Association (CABA)

09:05 Introduction of Chinese-American BioMedical Association (CABA)

Kevin Fang, Ph.D., Senior Director, Sunovion
President, Chinese-American BioMedical Association (CABA)

09:15 ~ 16:30 **Private 1-on-1 Sessions between Investors and Startup Companies (Berkshire Room)**

09:15 ~ 10:35 **Session I: Entrepreneurship in Today's Biotech Industry (Auditorium)**
Session Chair/Moderator, **Lan Cao**, Ph.D., CRISPR Therapeutics

Biotech has been cultivating a hotbed of entrepreneurs. Biotech is not only a thriving industry with a wealth of possibilities, also it allows daring entrepreneurs to leave their stamp on world problems. Helping improve surgery, develop cures, or vaccinate against deadly diseases. What makes a biotech entrepreneur? In this session, four successful biotech entrepreneurs will share their personal stories about how they started from scratch and built companies that are helping the lives of patients.

09:15 Rules of the Road – Biotechnology Entrepreneurship

David Lucchino, MBA
Co-founder, President and CEO, Frequency Therapeutics
Incoming Chairman, Board of Directors, Massachusetts Biotechnology Council

Boston has been ranked #1 as a cluster for early stage biotech companies for several years. The inescapable gravity of biotech's key clusters: the great consolidation of talent, capital, and returns has made Boston one of the most attractive places for biotech entrepreneurs. Mr. Lucchino will share his experiences in establishing several biotech companies in Boston, and his insights as the incoming BoD Chairman of MassBio.

09:35 Jacobio, a Novel Accelerator Model for Biotech Startups

Yinxiang Wang, Ph.D., Founder and Chairman, Beijing Jacobio Pharmaceuticals

Dr. Wang, former CEO/Co-founder of Betta Pharmaceuticals, will tell us about his new startup, Jacobio, an innovative approach to help scientists and entrepreneurs. With novel ideas, even without solid research results, a scientist can also get angel investment, laboratory platform, and even R&D team support in Dr. Wang's Jacobio.

09:55 Building a Biotech Company in China – Personal Experience

Yuele Shen, Ph.D., Founder & CEO, Beijing Biocytogen Co. Ltd.



2017 CABA INVESTMENT & ENTREPRENEURSHIP SYMPOSIUM

Many overseas Chinese scholars want to build a biotech company. How can you start a company in China; collaborate with VC's; and expand your business? Dr. Shen will relate his personal experiences and observations in China.

10:15 Building a Medical Device Startup Company in China
Yu Li, MBA, Co-founder, Bowing Medical

The medical device market in China has excellent growth potential. Mr. Li will share his experience of building a startup with medical diagnostic imaging CT products in China.

10:35 Coffee Break (Foyer)

10:50 ~ 11:50 Session II: Investors' Perspective on Biotech Investment and M&A (Auditorium)
Session Chair/Moderator: **Youxin Zhang**, Ph.D., Navigant

Surging innovation in biotech, especially in the field of oncology treatment, has attracted countless investors. Success stories, like Betta Pharmaceuticals and Biogen, create a promising vision of biotech-startups and encourage more talent from biopharmaceutical companies to chase their entrepreneurial dreams in China. How do you judge the potential value of a startup? Welcome to this session and hear more from three investors - from industry, venture capital, startups and an investment firm.

10:50 Crossing Barriers in Cross-border Investment
Yining Zhao, Ph.D., Venture Partner, Lilly Asia Ventures

With the increasing interest and influx of capital from China into US/EU biotech market, cross-border investment has become an emerging trend. This presentation will share some deep insights into this new investment paradigm from deal sourcing, structural building to post-deal management. The speaker will try to unveil the feasibilities, complexity and pitfalls of the business model in real-world scenarios.

11:10 Everest Medicines: Building a Partner of Choice in China
Sean Wuxiong Cao, Ph.D., MBA, Managing Director, C-Bridge Capital
President and Interim CEO at Everest Medicines

Access to innovative medicines in China currently lags behind that in the United States. Nearly half of all drugs approved by the US Food and Drug Administration (FDA) between 2012 and 2017 are still waiting to start the regulatory process in China. But ongoing reforms to China's regulatory environment are expected to accelerate development and approval times for imported innovative drugs by 2-5 years, heralding a new era of opportunity for the pharmaceutical industry.

11:30 Recent Acquisition Deals for Cancer Immunotherapy Companies
Han Ying, Ph.D., CSO, Sanpower Group; Global Strategic Consultant, Dendreon

Dendreon, with a FDA-approved cellular immunotherapy for prostate cancer, has been acquired for \$819.9 million in cash, by Sanpower Group. Dr.Han will share with us the story with more details and future prospects.

11:50 Lunch Break (Dining Room) and Exhibitor Show (Foyer)



2017 CABA INVESTMENT & ENTREPRENEURSHIP SYMPOSIUM

13:00 ~ 14:40 Session III: From Entry To Exit: What It Takes To Create A Viable Startup (Auditorium)

The world is awash in cool new tech startups, with huge winners achieving massive scale, there is always the enthusiasm in the biotech world to create the next big one. How to overcome the barriers to entry and how to make the right exiting strategy is of course the billion-dollar question. We hope experiences from the following successful stories may shine some light on your road to entrepreneurship.

Session Chair, **Bo Ying**, Ph.D., Director, Formulation and Drug Development, Trucode Gene Repair Inc.
Moderator: **Jun Wang**, Ph.D., VP of Discovery Biology, Shanghai Medicilon Inc.

13:00 From Startup to IPO

Jun Wang, Ph.D., VP of Discovery Biology, Shanghai Medicilon Inc.

When Medicilon was founded in 2004, most of the startup funds were from Dr. Chunlin Chen's family. Now Medicilon has grown into a leading international CRO with targeted revenue of 100 million RMB in 2018. I would like to share with you our story of "A CRO company's route to going public in China."

13:20 How a Protein Company Becomes a Great Partner

Mike Yiding Chen, CEO, Acrobiosystems

Starting with the basic service and conquering all the difficulties— see how Acro has been growing and becoming a great partner to help the whole pharmaceutical community.

13:40 The Early Investment Opportunities for Biomedical Care in China

Feng Li, Founding Partner, FreeS Fund

Currently more than 80% of the national social health insurance expenditures for major diseases go toward the purchase of imported drugs and supplies. The gap between China's current domestic medical resources and supply is apparent. It is an urgent priority to leverage the potential cost savings on core drugs - to reduce the absolute and relative contribution to healthcare expense. Therefore, it may be a great opportunity for early-stage investors to evaluate new drug research and development in the domestic industry.

14:00 From Seed to Exit in 15 Months: the Delinia Story

Lijun Wu, Ph.D., Entrepreneur-In-Residence, Atlas Venture

I will focus this presentation on my most recent experience working at Delinia, a virtual start-up company. Delinia was funded by Atlas and Sofinnova in late 2015 and had \$35M seed and series A financing. In early 2017, ~15 months after the seed round, Delinia was acquired by Celgene for \$775M including \$300M upfront payment.

14:20 Session IV: Panel Discussion

All-things-Considered for Biomedical Entrepreneurship and Investment: Technology, Funding, and Legal Issues

Session Chair/Moderator: **Jian Shao**, MBA, Senior Director, BD & Investment, Simcere of America, Inc.



2017 CABA INVESTMENT & ENTREPRENEURSHIP SYMPOSIUM

Biomedical Entrepreneurship is comprehensive and systematic endeavor, which includes market, capital, science, technology, operation, strategy, legal and accounting issues etc. There are many pitfalls as well as solutions. In this session, a blue-ribbon panel of speakers, with first-hand experience, will share their thoughts and lessons learned.

Jiawen Han, Ph.D., Head of BD, New England, Qilu Pharmaceutical

Chong Xu, Ph.D., Senior Associate, F-Prime Capital

Jing Li, Ph.D., Senior Vice President, Wuxi Biologics

Weimin Tang, Ph.D., Executive Director, Hengrui Therapeutics Inc.

Chen Chen, Ph.D., J.D., Cooley LLP

Geoffrey Spolyar, J.D., Cooley LLP

15:30 Coffee Break (Foyer)

15:50 Startup Pitch Competition (Auditorium)

16:50 CABA High School Student Research Award & Startup Pitch Award (Auditorium)

Susan Qu, Ph.D. MBA, Sanofi Genzyme

Cindy Yang, MBA, Biogen

17:30 Closing Remarks (Auditorium)

18:00 ~ 19:30 Cocktail Reception (Foyer; Ticket sold separately)

Two Positions Are Opening



ACROBiosystems is a leading manufacturer of recombinant proteins. We provide high quality protein reagents to the pharmaceutical research community. ACROBiosystems currently has two open positions of RESEARCH SCIENTIST in its Newark Delaware site, and Sales and Business Development Manager/Representative in the Bay Area and Boston sites.

• **Position: RESEARCH SCIENTIST (Full-Time/Regular)**

Location: Newark, Delaware, United States

Description: The Research Scientist is a key member of the Lab operation department, which reports to the Lab Operations Director. The position is responsible for immuno-assay development, including method development and troubleshooting. The qualified candidate will perform technical reviews of analytical data and methods; plan and direct development of quantitative immunoassays and anti-drug antibody immunoassays; interact with clients, get involved in assay design, and assist business development in the preparation of proposals.

Master's degree or doctorate in related field or equivalent combination of education and experience are required. Overtime and weekend work are required.

• **Position: SALES AND BD MANAGER/REPRESENTATIVE (Full-Time/Regular)**

Location: San Jose, California and Boston, Massachusetts

Description: The position is responsible for generating and pursuing new clients, as well as increasing from the company's existing client base in the assigned territory. The position will also be extensively involved in building customer relationships and providing support, both technical support and other support, to her/his clients.

The position will also be responsible for identification and pursuit of collaboration opportunities, through which the company may acquire new technologies and new business assets.

Contact Info: Tel: +1 (408) 768-9619 Charmaine Chen Email: hr@acrobiosystems.com

BOSTON

SEPT 30, 2017

PRESENTED BY CABA



Sean Wuxiong Cao, Ph.D., Managing Director, C-Bridge Capital

Dr. Sean Cao is the Managing Director of C-Bridge Capital, a health care VC fund based in China with \$700M AUM. Prior to that, Dr. Cao was VP of Global Business Development at Simcere Pharmaceutical Group, responsible for the global BD strategy for Simcere. Dr. Cao was also the President and Board Director at Simcere of America. Before that, Dr. Cao was the Senior Director of Alternative Partnership, Evaluation & Expertise at Sanofi, where he led the externalization effort in Global R&D. Before Sanofi, Sean was an associate at New Leaf Venture Partners, a leading healthcare VC firm based in New York. Sean worked in the pharmaceutical and diagnostic industries for over eight years before joining New Leaf, first at Aventis, then at Johnson & Johnson.

Sean holds a Ph.D. in Microbiology from the University of Virginia, an MBA with honor from Wharton School of University of Pennsylvania, and a B.Sc. in Microbiology from Nankai University.



Chen Chen, Ph.D. J.D., Cooley LLP

Dr. Chen Chen is an associate in the patent counseling and prosecution practice. He prepares and prosecutes US and foreign patent applications in various technology fields, including small molecule pharmaceuticals, immunology, plant sciences, virology, and cell biology. Prior to joining Cooley, he was a technology specialist and then an associate at the Boston office of Mintz Levin. Chen investigated the cellular entry and transport of influenza virus and polymer-mediated gene delivery in his doctoral research.

Dr. Chen received his JD degree from Suffolk University and PhD in Chemistry from Harvard University.



Mike Yiding Chen, CEO, Acrobiosystems

Mike (Yiding) Chen, the CEO of ACROBiosystems, previously worked as application scientist and project manager at Life Technologies and Thermofisher respectively before he founded ACROBiosystems in 2010, a biotech company that is committed to providing quality protein reagent products specially designed for antibody drug development. He has over 15 years experience in pharmaceutical and biotech industry.



2017 CABA INVESTMENT & ENTREPRENEURSHIP SYMPOSIUM



Ying Han, Ph.D., CSO, Sanpower Group; Global Strategic Consultant, Dendreon

Han Ying received his PhD in cancer biology from Stanford University. He did his postdoctoral training with Dr. Steven Rosenberg at US National Cancer Institute. He is the Chief Scientific Officer for Sanpower Group and global strategic consultant for Dendreon.



Jiawen Han, M.D., Ph.D., Head of BD, New England, Qilu Pharmaceutical


Jiawen Han MD, PhD, 22 years of experiences in drug discovery/development and business development. Currently, Dr. Han is Head of Business Development New England, Qilu Pharmaceutical. Previously, Dr. Han was Vice President of WuXi Biologics in Shanghai. Prior to that, he was Director of Biologics Discovery in the Innovation Center China, AstraZeneca in Shanghai. He also served as Director of Preclinical Development at Aileron Therapeutics, Inc. and Head of ADC projects at ImmunoGen, Inc.

Before working at Industry, he was a Postdoctoral Fellow in Biology Department at MIT. Dr. Han received his M.D. from Peking University Medical School and PhD from University of Rochester. Dr. Han was invited to speak and serve as a chair at many Biotech/Pharmaceutical conferences.



Jing Li, Ph.D., Senior Vice President, Wuxi Biologics

Dr. Jing Li is currently the Senior Vice President of WuXi Biologics, leading the Biologics Discovery Division. He joined WuXi AppTec in 2013 as Vice President of Biologics Discovery. Since then Dr. Li has formed a first-class biologics drug discovery team, built up proprietary multiple comprehensive biologics drug discovery platforms, established the working process from target all the way to IND filing, and serviced both domestic and global clients by this integrated biologics R&D platform. Before joining WuXi AppTec, he worked in Novartis Biologics Center as Senior Manager of Portfolio & Alliance Management. Before that, he worked in Novartis Oncology as Lab Head and Program Team Head. Prior to Novartis, he worked in Wyeth (now Pfizer) as Senior Scientist and Project Leader.



Yu Li, MBA., Co-founder, Bowing Medical

Nathan Li cofounded Bowing Medical in 2012 to develop CT diagnostic imaging product in China. Prior to that, Nathan specialized in bringing high tech products to global market including medical devices, NIR spectroscopy, telecommunication systems and semiconductor manufacturing equipment. Nathan held MBA from Babson College and MS from Boston University..



David Lucchino, MBA, Co-founder, President and CEO, Frequency Therapeutics.

David is the Co-founder, President and Chief Executive Officer of Frequency Therapeutics. He has over 20 years of entrepreneurial experience and has played an integral role in launching, building and operating many successful companies in the life sciences and other innovation sectors. Previously, David was the President and Chief Executive Officer of Entrega Bio. David's first MIT-based startup was Semprus BioSciences. Prior to Semprus, David was a Senior Executive at the leading venture capital firm, Polaris Partners. David launched his career in the life sciences by co-founding LaunchCyte, an investment firm specialized in commercializing biomedical intellectual property. While David currently serves as Vice Chairman of the Board of Directors of MassBio, he was recently elected to be the new Chairman and will lead the organization in 2018.

David earned an MBA at the MIT Sloan School of Management as an Alfred P. Sloan Fellow, an M.S. from Syracuse University and a B.A. from Denison University.



Yuelei Shen, Ph.D., Founder & CEO, Beijing Biocytogen Co. Ltd.

Dr. Shen founded Biocytogen in 2008 and leads the company to become a prestigious gene engineered mouse/rat provider and preclinical service entity.

He has nearly 20 years of experience in immunology, molecular biology and gene knockout model animal production and research, and has mainly investigated the pathological mechanisms involved in autoimmune disease using mouse models. Several gene-engineered mouse strains generated by Dr. Shen have been used by hundreds of labs worldwide, the studies have been published in top journals such as Nature, Nature Immunology, and Immunity.

Dr. Yuelei Shen received his B.Sc. from Wuhan University and Ph.D. from University of Massachusetts Medical school, then move to NYU medical school for postdoctoral training in Dr. Littman's lab.



2017 CABA INVESTMENT & ENTREPRENEURSHIP SYMPOSIUM



Geoffrey Spolyar, J.D., Cooley LLP

Geoffrey Spolyar focuses his practice on the representation of life sciences companies in a broad range of commercial and financial matters. Much of his practice is devoted to negotiating and drafting corporate partnership agreements, licensing arrangements, strategic alliances, joint venture agreements and other complex technology transactions. Prior to joining Cooley, Geoffrey was senior counsel at Amgen in Thousand Oaks, California where he represented Amgen in a number of strategic alliances including its joint venture with Astellas Pharma in Japan and its collaboration with AstraZeneca regarding several of Amgen's inflammation programs.

Dr. Spolyar received his JD degree from the University of Southern California.



Jun Wang, Ph.D., VP of Discovery Biology, Shanghai Medicilon Inc.

Dr. Jun Wang, VP of Discovery Biology at Shanghai Medicilon Inc. Before joining Medicilon, Dr. Wang was the VP and Head of Biology at Sundia MediTech. Dr. Wang served at Merck & Co., Inc. for 9 years, leading multiple drug-discovery programs on principles of food-animal growth promotion, infectious diseases, diabetics and cardiovascular diseases. Prior to Merck, Dr. Wang worked at a biotech company in Seattle as the head of biology section and served as an assistant professor in University of Texas Southwestern Medical Center and University of Washington for 5 years.

Dr. Wang got his BS in biophysics from Fudan University and received his Ph.D. in molecular biology and biochemistry from Kobe University (Japan). He had his post-doc training in the Department of Pharmacology at UT Southwestern Medical Center.



Lijun Wu, Ph.D., Entrepreneur-In-Residence, Atlas Venture

Senior Vice President of Preclinical and Early Clinical Development at Delinia. Before joining Delinia, Dr. Wu held various senior leadership positions including Vice President of Biology and Preclinical Research and Development at Concert Pharmaceuticals, Vice President of Discovery Research at Resolvix Pharmaceuticals, Executive Director of Cardiovascular Research at the Novartis Institutes for BioMedical Research, and Director of Molecular and Cellular Pharmacology at Millennium Pharmaceuticals. Dr. Wu has over 20 years of R&D experience. She has led teams to advance numerous projects from discovery to preclinical and clinical development with both small molecules and biologics.

Dr. Wu received her Ph.D. in Biochemistry, Molecular Biology and Cell Biology from Northwestern University and completed a postdoctoral fellowship at Johns Hopkins University School of Medicine.



2017 CABA INVESTMENT & ENTREPRENEURSHIP SYMPOSIUM



FreeS Fund

By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stage startups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology



Feng Li


Feng focuses on E-commerce, deep technology, online education, new generation lifestyle businesses and O2O enterprises. Previously as a partner at IDG-Accel, he led investments on a series of successful projects, including CreditEase, Zhubajie, Prosper, Three Squirrels, Tongbanjie, Didapinche, Bilibili, Coinbase, Changingedu, Dig Fortune, Helijia, Wangli Finance Group, Yodo Fortune, FraudMetrix, Liulishuo, Ripple Labs, Wecash, Jiang Xiaobai, Hstyle, baifendian, and bairong. Among them, CreditEase went public in 2015, Zhubajie and Prosper successfully joined Billion Dollar Club. The return of investment at seed stage for Three Squirrels, Tongbanjie, and Wangli Finance Group are now up to 50 times. Feng led the establishment of IDG-Accel's post-investment service system, providing help to early stage startups. Services include public relations, marketing, and human resources. He promoted topic investment strategy including Internet brand, Fintech, the 90s entrepreneurs project, C2C of O2O and economy sharing approach.

Feng obtained B.S. in Chemistry from Peking University, and M.S. in Chemistry from University of Rochester.



Fidelity F-Prime Capital

We are a group of entrepreneurs, operators, doctors, scientists, and investors. We have low egos, but big vision. In healthcare, we focus on Biopharmaceuticals, MedTech, and Healthcare IT/Services in a stage-agnostic fashion. We are constantly searching for the next big thing in healthcare, and sometimes, we will found that something ourselves.



Chong Xu

Chong is a Senior Associate at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company's Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.



2017 CABA INVESTMENT & ENTREPRENEURSHIP SYMPOSIUM

Lilly Asia Ventures 礼来亚洲基金



Lilly Asia Ventures, founded in 2008, is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China. Its investors include Eli Lilly & Co., a Fortune 500 company and one of the most globalized and innovative pharmaceutical companies in the world. As a leading biomedical venture fund in China, Lilly Asia Ventures provides wise capital, industry expertise, and global resources to its portfolio companies to accelerate their growth. Our investment size is usually between US \$5 and \$15M per round, and we only take minority stake in a company (<20%). In most cases, we desire a board seat or observation rights. After we make an investment, we always devote tremendous time and energy to provide value-added services and help our portfolio companies maximize its success.



Yining Zhao, Ph.D.

Dr. Yining Zhao is currently a Venture Partner at Lilly Asia Ventures (LAV) responsible for cross-board investment between US and China. He has also co-founded several US biotech companies and is CEO of three portfolio companies, namely, Just Biotherapeutics (China), Veritas Genetics (China), and NuBiyota China Inc., which are specialized in biologics development, genomic sequencing and microbiome therapeutics, respectively.

Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), Ph.D. in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). Yining has contributed more than 30 peer-reviewed publications and book chapters.



Return Energy International

Return Energy International (REI) was established in Dec 2014. The company is engaged in the identification, evaluation, and marketing of global E&P assets to Upstream investors. Return Energy Team have 80+ years industry experience. With a wealth of industry knowledge, REI works with international investors to acquire quality E&P assets aligned with their specific financial metrics, risk tolerance, geographic preferences and commodity mix.

As a strong team we are ready to tackle anything from the most complex O&G projects to minor consulting projects. We are fueled by our commitment to excellence and go the extra mile to make sure our clients are completely satisfied with the presented work and positive returns. Call to schedule an initial consultation today.

Haiping Ni, Ph.D.

Founding Shareholder, Bohan Health
President, REI investment
Managing Director, Access America Investments, LLC
MBA, Rice Business School
BA, Tianjin Foreign Studies University

BOSTON

SEPT 30, 2017
PRESENTED BY CABA



LEGEND CAPITAL 君联资本

Legend Capital 君联资本

Legend Capital is now managing several USD funds and RMB funds with a total AUM RMB35 bn, and focuses on innovation and growth enterprises with operations in China or related to China. The core business of Legend Capital is early-stage Venture Capital and expansion-stage Growth Capital investment.

By 2016, Legend Capital has invested in over 300 companies, of which over 50 are successfully listed on domestic or overseas capital market, besides, around 40 companies achieved exit through M&A.

Jian Shu, Ph.D.

Venture Partner, Legend Capital;
Helen Hay Whitney Fellow, Eric Lander lab, Broad Institute;
Visiting Scientist, Rudolf Jaenisch lab, Whitehead Institute

Tsuihang New District



中山翠亨新区

ZHONGSHAN TSUIHANG NEW DISTRICT

Tsuihang New District is a major economic development platform approved by the Guangdong Provincial Government in 2012.

As the end of 2016, the starting area hosted 90 enterprises with a total investment of RMB 68.8 billion. These companies mainly operate in the healthcare & pharmaceutical, marine equipment and intelligent equipment industries, etc. The industrial output value of these enterprises above designated size totalled RMB 20 billion.

Shaohui Huang, Ph.D.

Dr. Huang currently serves as a Business Consultant for Tsuihang New and the Managing Director of Zhongshan Business Office Boston Station. He is also the CEO/President/Co-founder of LightEdge Technologies Ltd. (Cuiheng New District, Zhongshan, Guangdong).

Dr.Huang received his Ph.D. degree in biochemistry from the University of Kansas in 1998.



JacoBio

Beijing JacoBio drug development Co., Ltd. was founded in 2015, the company is committed to the healthy development of mankind, the development of innovative drugs with independent intellectual property rights in the world, our vision is to become a leader in innovation, research and development of new drugs do booster entrepreneurs, to provide more products and solutions for the healthy development of human.



2017 CABA INVESTMENT & ENTREPRENEURSHIP SYMPOSIUM



Yinxiang Wang, Ph.D.

Former founder and CEO/CSO of Betta Pharmaceuticals. Jacobio Pharmaceuticals' Chairman and ETown-Jacobio Biocapital's chairman. Dr. Wang led the developed Icotinib Hydrochloride (Conmana®), a new molecular entity (NME) for lung cancer. The project won the 1st prize of National Science and Technology Award, the gold medal of WIPO-SIPO Award in 2012 and 2014, and the 1st prize of Science and Technology Award in Zhejiang province. Betta went public at Shenzhen Exchange in 2016. Betta formed JV with Amgen (Amgen-Betta Pharmaceuticals) in 2013 and Dr. Wang served as GM (2013-2017).

Dr. Wang is also the Chairman, New Drug R&D Committee of China.

Pharmaceutical Innovation and Research Development Association (PHIRDA); Associate Chairman, Oncology Drug Clinical Research Committee of Chinese Pharmaceutical Association. Dr. Wang was selected to be the national "Recruitment Program of Global Experts (1000-experts plan)" in 2012. Dr. Wang was selected to be the winner of 2017 CABS K.Fong Award in Life Sciences.



HENGRUI THERAPEUTICS, INC.

make it matter

Hengrui Therapeutics, Inc. (HTI)

Hengrui Therapeutics, Inc. is a Princeton, NJ-based clinical development company dedicated to developing and commercializing innovative pharmaceuticals to address global unmet medical needs. Our current therapeutic area of focus is oncology, Immunology, Pain and Metabolic diseases, with multiple clinical-staged assets for immuno-oncology and target therapies in the pipeline. The company was established in 2016 with the help of a \$100M investment from Jiangsu Hengrui Medicine and a blue chip wall street VC.

(<http://www.fiercebiotech.com/biotech/hengrui-therapeutics-gains-100m-investment-to-further-cancer-pipeline>)



Weimin Tang, Ph.D.

Dr. Weimin Tang is currently the Head of US Business Development/Executive Dir. Jiangsu Hengrui Medicine. He was trained as cancer biologist with PhD in Biochemistry where he studied under Dr. CS Yang at Rutgers University and went for industrial career after graduation. He has accumulated more than 20 years of research and business management experiences with global pharmaceutical companies and biotechs such as Synaptic Pharmaceutical, BMS, JNJ, Sanofi, Crown Biosciences and currently Hengrui Medicine. Through his industry career, he expanded his function from basic biology to high throughput screening, DMPK and business management. Before he joined Jiangsu Hengrui Medicine, he was Vice President of global business development and drug discovery at Crown Bioscience.

Dr. Tang received his Bachelor's Degree from Zhejiang University, Master Degree from Chinese Academy of Sciences.



SPONSORS

BIOSYSTEMS
Acro

Cooley

 **HENGRUI THERAPEUTICS, INC.**
make it matter

 **BIOCYTOGEN**


Precision. Punctuality. Commitment to Excellence.

 **Medicilon Inc.**
Integrated Drug Discovery Services

F/PRIMESM


FREES

 **中山翠亨新区**
ZHONGSHAN TSUIHANG NEW DISTRICT


NAVIGANT



ASCLSRC
AMERICAN SOUTHERN CALIFORNIA LIFE SCIENCE RESEARCH CENTER

**LEGEND
CAPITAL**
君联资本

Chinese-American BioMedical Association

美中生物医药协会



CABA Mission Statement

- To promote science, technology, and business collaboration in biotech/pharmaceutical industry ;
- To build and maintain a platform through cohesive scientific, professional, and cultural connection that provides high quality services;
- To facilitate networking among scientists, professionals, and entrepreneurs in academia, biotech/pharmaceutical industry and regulatory agencies;
- To embrace advancement of science and commercialization of innovation that will benefit human health;
- To foster collaborations between the United States and China for the development of better biotech/pharmaceutical therapeutics.

About CABA

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potential.

CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves its members.

Contact Us

If you have any comments, suggestions or feedback to our organization and our events, please feel free to contact us at info@cabaweb.org. Your comments are important for us to improve in the future. Thank you very much!

Website: www.cabaweb.org
Email: info@cabaweb.org
P. O. Box 426157
Cambridge, MA 02142

